Christine McCluskey

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

Alyssa R. Richman, Monika S. Kowalczyk, Shuqiang Li, 2018, Nature.

Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma

Katrina H. Smith, P. Wen, R. Jain, 2018, Clinical Cancer Research.

A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients

Katrina H. Smith, T. Mikkelsen, R. Beroukhim, 2015, Clinical Cancer Research.

Interim analysis of a phase I/II study of panobinostat in combination with bevacizumab for recurrent glioblastoma.

Katrina H. Smith, R. Beroukhim, P. Wen, 2013 .

Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

P. Wen, R. Jain, J. D. de Groot, 2020, Clinical Cancer Research.

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma

Katrina H. Smith, R. Beroukhim, P. Wen, 2015, Neurology.

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.

Katrina H. Smith, R. Beroukhim, P. Wen, 2015, Neuro-oncology.

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.

Sankha S. Basu, Susan M. Chang, W. Yung, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activity of PD-1 blockade with Nivolumab among patients with recurrent atypical/anaplastic meningioma: Phase II trial results.

Raymond Y Huang, R. Beroukhim, P. Wen, 2021, Neuro-oncology.